Paratek expands commercial portfolio with Optinose

Paratek Pharmaceuticals has completed the acquisition of Optinose, valued at almost $330m, broadening its commercial product offerings.

May 24, 2025 - 06:00

Paratek expands commercial portfolio with Optinose

Paratek Pharmaceuticals has completed the acquisition of Optinose, valued at almost $330m, broadening its commercial product offerings.

Read the original article

Tags:

Previous Article

Sanofi buys Vigil Neuroscience for $470m in Alzheimer’s push

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Opinion: Former Surgeon General Jerome Adams: Prioritize new antivirals for Covid

Opinion: Former Surgeon General Jerome Adams: Prioritiz...

Jun 22, 2023

Why doesn’t the U.S. have more Black midwives?

Why doesn’t the U.S. have more Black midwives?

Sep 18, 2023

STAT+: Facing headwinds, Teladoc tests its bet on whole-person care

STAT+: Facing headwinds, Teladoc tests its bet on whole...

Apr 27, 2023